CytRx Corporation
Los Angeles, CA, US· latest recorded location
CytRx Corporation is named on 28 US grants and 16 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 28
- Published applications
- 16
- Inventors
- 64
- Granted in 2026 so far
- 0
- Most recent grant
- 5 Jan 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 3 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 1 |
| 2003 | 0 | 0 |
| 2004 | 2 | 1 |
| 2005 | 0 | 2 |
| 2006 | 3 | 1 |
| 2007 | 0 | 1 |
| 2008 | 2 | 1 |
| 2009 | 1 | 3 |
| 2010 | 2 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 2 | 2 |
| 2020 | 0 | 0 |
| 2021 | 1 | 0 |
By publication year.
Technology areas
Share of 44 documents
- A61KMedicines and medical preparations35
- A61PTherapeutic uses of medicines32
- C08GMacromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds15
- C07DHeterocyclic compounds14
- C07HSugars5
- C08LCompositions of macromolecular compounds5
- C07CAcyclic or carbocyclic compounds3
- Y02PLow-carbon manufacturing2
- A61BMedical diagnosis and surgery1
- A61FFilters implantable into blood vessels1
Recent patents
- Cytotoxic agents for the treatment of cancer5 Jan 2021US 10,881,678 B2
- Anthracycline formulations25 Jun 2019US 10,328,093 B2
- Cytotoxic agents for the treatment of cancer7 May 2019US 10,278,981 B2
- Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof29 Jun 2010US 7,745,465 B2
- Carboxamidine derivatives and their use in the treatment of vascular diseases6 Apr 2010US 7,691,849 B2
- Cytotoxic agents for the treatment of cancer21 Nov 2019US 2019/0350952 A1
- Delivery systems for controlled drug release3 Jan 2019US 2019/0002484 A1
- Anthracycline formulations30 Nov 2017US 2017/0340655 A1
- Cytotoxic agents for the treatment of cancer31 Mar 2016US 2016/0089388 A1
- Anthracycline formulations3 Dec 2015US 2015/0342975 A1
Most cited
By later US patents
- Compositions and methods for growth promotion62US 5,824,322 A1998
- Polyoxypropylene/polyoxyethylene copolymers with improved biological activity61US 5,696,298 A1997
- Gel composition for implant prosthesis and method of use40US 5,407,445 A1995
- Polyoxypropylene/polyoxyethylene copolymers with improved biological activity39US 5,523,492 A1996
- Polyoxypropylene/polyoxyethylene copolymers with improved biological activity30US 5,567,859 A1996